Arbutus Biopharma Corp (NASDAQ:ABUS)
| 2.47 Delayed Data As of Dec 02 |  +0.14 / +6.01%Today’s Change | 1.85 Today|||52-Week Range 5.23 | -36.50% Year-to-Date |
Latest ABUS News | Press Releases
No recent news for Arbutus Biopharma Corp.
Today’s Trading
| Previous close | 2.33 |
| Today’s open | 2.32 |
| Day’s range | 2.26 - 2.51 |
| Volume | 54,297 |
| Average volume (3 months) | 869,632 |
| Market cap | $388.0M |
Data as of 3:59pm ET, 12/02/2022
Growth & Valuation
| Earnings growth (last year) | +16.84% |
| Earnings growth (this year) | +45.54% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +58.92% |
| P/E ratio | NM |
| Price/Sales | 37.61 |
| Price/Book | 2.12 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| --Cassiopea SpA | 0.00 | 0.00% |
| ---- | ||
| ---- | ||
| --Tempo Scan Pacific T... | 0.00 | 0.00% |
Data as of 01/04/2022
Financials
| Next reporting date | March 9, 2023 |
| EPS forecast (this quarter) | -$0.13 |
| Annual revenue (last year) | $11.0M |
| Annual profit (last year) | -$76.2M |
| Net profit margin | -693.91% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Warminster, Pennsylvania |
Forecasts
